코야 테라퓨틱스(COYA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.89 (+2.73%), 시가총액 $0.10B, 52주 최저~최고 $3.78 ~ $7.36.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clin
코야 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
코야 테라퓨틱스의 현재 주가는 $4.89 (+2.73%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
코야 테라퓨틱스의 시가총액은 약 $0.10B입니다.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeli